Acquired hypofibrinogenemia: current perspectives.
Acquired hypofibrinogenemia: current perspectives.
复制标题
DOI：
10.2147/jbm.s90693
复制
发表时间：
2016
影响因子：
2
通讯作者：
MacDonald SG
中科院分区：
文献类型：
--
作者：
Besser MW;MacDonald SG
获得性低纤维蛋白原血症最常见的原因是血液稀释和凝血因子的消耗。积极补充纤维蛋白原已成为现代大出血治疗的核心原则之一。确定患者纤维蛋白原水平的最佳方法仍然存在争议，特别是在获得性纤维蛋白原异常血症中，可能具有主要的治疗意义，这取决于选择哪种定量方法。这篇综述介绍了现有的实验室和护理点的方法，并讨论了相对的优势和局限性。它还讨论了目前纠正低纤维蛋白原血症的策略。
Acquired hypofibrinogenemia is most frequently caused by hemodilution and consumption of clotting factors. The aggressive replacement of fibrinogen has become one of the core principles of modern management of massive hemorrhage. The best method for determining the patient’s fibrinogen level remains controversial, and particularly in acquired dysfibrinogenemia, could have major therapeutic implications depending on which quantification method is chosen. This review introduces the available laboratory and point-of-care methods and discusses the relative advantages and limitations. It also discusses current strategies for the correction of hypofibrinogenemia.